Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Microbot Medical Inc.NASDAQ: MBOT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $222K fell 13.3% year over year, behind the -11.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.3% toward the trailing-twelve-month pace of -11.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.06M USD
- Year-over-year change
- -21.6%
- 4-year CAGR
- -6.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.06M | -21.6% |
| FY2024 | 2024-12-31 | 1.35M | -3.2% |
| FY2023 | 2023-12-31 | 1.39M | -20.4% |
| FY2022 | 2022-12-31 | 1.75M | +26.4% |
| FY2021 | 2021-12-31 | 1.39M | — |
Stock-Based Compensation vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.2% is the 7th highest of 10, against a peer median of -6.9%.
- Stock-based compensation amounts to 974.3% of revenue for MBOT, versus a peer median of 33.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.84M USD | +9.4% | +29.4% | 5.2% | |
| LTM Mar 2026 | CA$11.4M CAD | -21.5% | +28.8% | — | |
| LTM Mar 2026 | $7.93M USD | -41.7% | +10.8% | 11.0% | |
| LTM Mar 2026 | $7.45M USD | -5.5% | -9.2% | 5559.7% | |
| LTM Mar 2026 | $2.41M USD | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.28M USD | +4.3% | — | — | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
| LTM Mar 2026 | $1.45M USD | -10.0% | +4.6% | — | |
| LTM Mar 2026 | $1.02M USD | -11.2% | -15.5% | 974.3% | |
| LTM Mar 2026 | CA$190.87K CAD | -64.5% | — | 114.9% | |
| Peer median (excluding MBOT) | — | -6.9% | +10.8% | 33.9% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.39M | 1.75M | 1.39M | 1.35M | 1.06M |
| Change in Working Capital | 497K | (228K) | (11K) | 942K | (1.01M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | (584K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 497K | (228K) | (11K) | 942K | (424K) |
| Other Non-Cash Items | 1.39M | (7K) | 718K | 234K | 0 |
| Operating Cash Flow | (9.35M) | (11.55M) | (8.53M) | (8.83M) | (13.05M) |
| Capital Expenditures | (69K) | (84K) | (33K) | (25K) | (60K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (3.75M) | (10.06M) | (5.12M) | (82.93M) |
| Sales of Investments | 3.27M | 0 | 12.06M | 6.68M | 10.6M |
| Other Investing Activities | 0 | (3K) | 3K | 0 | 0 |
| Investing Cash Flow | 3.2M | (3.84M) | 1.97M | 1.54M | (72.38M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.15M) | (11.06M) | (2K) | 646K | 810K |
| Free Cash Flow | (9.42M) | (11.63M) | (8.57M) | (8.85M) | (13.11M) |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.